Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.
- Daniel Camprubí
- Alex Almuedo-Riera
- Helena Martí-Soler
- Alex Soriano
- Juan Carlos Hurtado
- Carme Subirà
- Berta Grau-Pujol
- Alejandro Krolewiecki
- Jose Muñoz
Publication date
January 2020
DOI Publisher
Public Library of Science (PLoS) Journal
PLoS ONEAbstract
Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2
Add to ORKG